Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BRIUMVI safely and effectively. See full prescribing information for BRIUMVI. BRIUMVI ®(ublituximab-xiiy) injection, for intravenous use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- generic_name
- ublituximab
- product_names
- ublituximab
- ndc
- 73150-150, 73150-150-06
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en